Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:IMAB NASDAQ:IMMX NASDAQ:IVVD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$19.72+1.3%$16.73$7.08▼$20.90$402.49M0.62114,518 shs609,079 shsIMABI-Mab$4.22-3.9%$4.47$0.60▼$6.79$344.61M1.452.17 million shs1.36 million shsIMMXImmix Biopharma$3.61+5.2%$2.34$1.34▼$3.66$113.31M0.23617,689 shs1.17 million shsIVVDInvivyd$2.23+14.9%$1.27$0.35▼$2.74$415.95M0.576.66 million shs6.79 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+1.34%+0.41%+27.72%+28.14%+70.44%IMABI-Mab-3.87%-26.86%+18.54%+100.00%+217.29%IMMXImmix Biopharma+5.25%+25.78%+76.10%+33.21%+121.47%IVVDInvivyd+14.95%+28.16%+82.79%+184.08%+125.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$19.72+1.3%$16.73$7.08▼$20.90$402.49M0.62114,518 shs609,079 shsIMABI-Mab$4.22-3.9%$4.47$0.60▼$6.79$344.61M1.452.17 million shs1.36 million shsIMMXImmix Biopharma$3.61+5.2%$2.34$1.34▼$3.66$113.31M0.23617,689 shs1.17 million shsIVVDInvivyd$2.23+14.9%$1.27$0.35▼$2.74$415.95M0.576.66 million shs6.79 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+1.34%+0.41%+27.72%+28.14%+70.44%IMABI-Mab-3.87%-26.86%+18.54%+100.00%+217.29%IMMXImmix Biopharma+5.25%+25.78%+76.10%+33.21%+121.47%IVVDInvivyd+14.95%+28.16%+82.79%+184.08%+125.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$12.00-39.15% DownsideIMABI-Mab 2.86Moderate Buy$7.6781.67% UpsideIMMXImmix Biopharma 2.00Hold$8.00121.61% UpsideIVVDInvivyd 2.57Moderate Buy$5.14130.38% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, AMRN, IVVD, and IMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025IMMXImmix BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025AMRNAmarinWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.0010/20/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/17/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $9.0010/15/2025IVVDInvivydZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/8/2025AMRNAmarinWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMABI-MabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025IMMXImmix BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IVVDInvivydWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.00 ➝ $2.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.78N/AN/A$23.62 per share0.83IMABI-MabN/AN/AN/AN/A$2.47 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$0.48 per shareN/AIVVDInvivyd$25.38M18.84N/AN/A$0.56 per share3.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)IMABI-Mab-$22.23M-$0.36N/AN/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)IMMXImmix Biopharma-$21.61M-$0.77N/AN/AN/AN/A-205.35%-110.63%11/11/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A20.27N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)Latest IMMX, AMRN, IVVD, and IMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025IMABI-Mab-$0.07N/AN/AN/AN/AN/A11/13/2025Q3 2025IVVDInvivyd-$0.01N/AN/AN/A$12.00 millionN/A11/11/2025Q3 2025IMMXImmix Biopharma-$0.19N/AN/AN/AN/AN/A10/29/2025Q3 2025AMRNAmarin$0.31N/AN/AN/A$42.04 millionN/A8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/8/2025Q1 2025IMMXImmix Biopharma-$0.21-$0.22-$0.01-$0.22N/AN/A7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34IMABI-MabN/A22.8222.82IMMXImmix BiopharmaN/A1.231.23IVVDInvivydN/A1.331.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%IMABI-Mab38.38%IMMXImmix Biopharma11.26%IVVDInvivyd70.36%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%IMABI-Mab22.10%IMMXImmix Biopharma55.40%IVVDInvivyd25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.00 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableIMMXImmix Biopharma933.04 million14.73 millionOptionableIVVDInvivyd100214.41 million159.95 millionOptionableIMMX, AMRN, IVVD, and IMAB HeadlinesRecent News About These CompaniesInvivyd (NASDAQ:IVVD) Downgraded to "Strong Sell" Rating by Zacks ResearchOctober 17, 2025 | marketbeat.comCantor Fitzgerald Estimates Invivyd FY2025 EarningsOctober 10, 2025 | marketbeat.comInvivyd (IVVD) Is Up 34.4% After FDA Clears Late-Stage COVID Antibody Program—What’s ChangedOctober 9, 2025 | finance.yahoo.comInvivyd (NASDAQ:IVVD) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comInvivyd (IVVD): Assessing Valuation After FDA Clears Phase 3 COVID-19 Antibody TrialOctober 8, 2025 | finance.yahoo.comD. Boral Capital Maintains Invivyd (IVVD) Buy RecommendationOctober 7, 2025 | msn.comInvivyd announces IND clearance, alignment with FDA on VYD2311 programOctober 6, 2025 | msn.comCantor Fitzgerald Initiates Coverage of Invivyd (IVVD) with Overweight RecommendationOctober 6, 2025 | msn.comD. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00October 6, 2025 | marketbeat.com5 Analysts Have This To Say About InvivydOctober 6, 2025 | benzinga.comInvivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 6, 2025 | marketbeat.comInvivyd (NASDAQ:IVVD) Now Covered by Cantor FitzgeraldOctober 6, 2025 | marketbeat.comInvivyd’s VYD2311 Receives FDA Clearance for TrialsOctober 6, 2025 | tipranks.comInvivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDOctober 6, 2025 | globenewswire.comInvivyd files $350M mixed securities shelfOctober 2, 2025 | msn.comInvivyd (NASDAQ:IVVD) Stock Price Down 1.8% - Here's WhyOctober 1, 2025 | marketbeat.comInvivyd Appoints Paul B. Bolno, M.D. to Its Board of DirectorsSeptember 25, 2025 | markets.businessinsider.comInvivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody ApprovalSeptember 25, 2025 | finance.yahoo.comInvivyd Appoints New Director Amid Nasdaq ComplianceSeptember 25, 2025 | tipranks.comInvivyd, Inc. Appoints Dr. Paul B. Bolno to Board of DirectorsSeptember 24, 2025 | quiverquant.comQInvivyd Appoints Paul B. Bolno, M.D.September 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, AMRN, IVVD, and IMAB Company DescriptionsAmarin NASDAQ:AMRN$19.72 +0.26 (+1.34%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$20.08 +0.36 (+1.80%) As of 10/24/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.I-Mab NASDAQ:IMAB$4.22 -0.17 (-3.87%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.39 +0.18 (+4.15%) As of 10/24/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Immix Biopharma NASDAQ:IMMX$3.61 +0.18 (+5.25%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.66 +0.06 (+1.52%) As of 10/24/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Invivyd NASDAQ:IVVD$2.23 +0.29 (+14.95%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.23 0.00 (0.00%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
